Primary mediastinal B-cell lymphoma - metabolic and anatomical features in 18FDG-PET/CT and response to therapy.
OBJECTIVE
Determining the role of PET/CT imaging in the evaluation of treatment efficacy in primary mediastinal B-cell lymphoma (PMBCL).


METHODS
Retrospective analysis of seven PMBCL patients, treated at the University Hospital in Krakow, with interim PET/CT after the third course of chemo-immunotherapy.The analysis was based on the calculation of exact tumour volume and metabolic activity, compared with initial values (directly after diagnosis).


RESULTS
Patients (five females, two males, average age 26.2 years, range 18-40 years), in clinical stage IIBX at diagnosis, were treated with eight cycles of R-CHOP-14 regimen, with radiotherapy consolidation (7/7) and central nervous system prophylaxis (6/7). The observed decrease in tumour volume between the initial staging and the interim PET ranged 72-89%. The mean ΔSUVmax reduction between initial (when available) and interim PET was 87% (range 84-89%). In 3/7 cases in the interim PET/CT, the uptake of the tumour was higher than the liver (Deauville Criteria score 4-5), and in 4/7 it was lower than the liver but higher than mediastinal blood pool structures (score 3 according to Deauville Criteria). After a median follow-up of 58 months - OS and EFS is 100%.


CONCLUSIONS
The excellent clinical outcome in the study group corresponds with very good metabolic and volumetric response in the interim PET. The ΔSUVmax seems to be easier in implementation and has a more significant impact than other measurements.
Jagiellonian University Collegium Medicum, Krakow, Poland; The authors had equal participation in the study design.
Anna
A
Kocurek
The Franciszek Lukaszczyk Oncology Centre, Bydgoszcz, Poland; The authors had equal participation in the study design.
Bogdan
B
Małkowski
Jagiellonian University Collegium Medicum, Krakow, Poland.
Agnieszka
A
Giza
Jagiellonian University Collegium Medicum, Krakow, Poland.
Wojciech
W
Jurczak
X-ray computed mediastinal neoplasms/radiography; diffuse/radionuclide imaging; large B-cell; lymphoma; tomography
Ann Oncol. 2002 Sep;13(9):1356-63
12196360
J Clin Oncol. 2009 Apr 10;27(11):1742-3
19273698
Blood. 1999 Jul 15;94(2):429-33
10397709
J Clin Oncol. 2007 Feb 10;25(5):579-86
17242396
J Clin Oncol. 2014 Sep 20;32(27):3059-68
25113753
Oncologist. 2006 May;11(5):488-95
16720849
Ann Hematol. 2014 Aug;93(8):1297-304
24595734
Med Oncol. 2014 Mar;31(3):880
24504845
Eur J Nucl Med Mol Imaging. 2013 Apr;40(4):496-504
23344136
J Nucl Med. 2007 Oct;48(10 ):1626-32
17873129
Blood. 2012 Mar 1;119(9):2066-73
22234681
Leuk Lymphoma. 2009 Aug;50(8):1257-60
19544140
Cancer. 2013 Mar 15;119(6):1195-202
23212736
J Nucl Med. 2009 Apr;50(4):527-33
19289424
Crit Rev Oncol Hematol. 2008 Dec;68(3):256-63
18774728
Curr Hematol Malig Rep. 2014 Sep;9(3):273-83
24952250
Br J Cancer. 2004 Aug 31;91(5):850-4
15266320
Oncology. 1998 Jul-Aug;55(4):284-8
9663416
Oncologist. 2012;17(2):239-49
22282906
Leukemia. 2016 Jan;30(1):238-42
25971363
Haematologica. 2000 Jun;85(6):613-8
10870118
Int J Radiat Oncol Biol Phys. 2015 May 1;92 (1):113-21
25863759
Hematol Oncol. 2015 Dec;33(4):145-50
25256959
Int J Radiat Oncol Biol Phys. 2013 Oct 1;87(2):311-6
23916170
Ann Oncol. 2011 Mar;22(3):664-70
20724576
J Clin Oncol. 2014 Sep 20;32(27):3048-58
25113771
Am J Surg Pathol. 1996 Jul;20(7):877-88
8669537
Blood. 2015 Aug 20;126(8):950-6
26089397
J Clin Oncol. 2014 Jun 10;32(17 ):1769-75
24799481